Severe liver injury caused by semaglutide injection
10.3760/cma.j.cn114015-20230118-00028
- VernacularTitle:司美格鲁肽注射液致重度肝损伤
- Author:
Huanli YIN
1
;
Lei YU
1
;
Lan SU
1
;
Fengbo WU
1
Author Information
1. 四川大学华西医院临床药学部，成都 610041
- Publication Type:Journal Article
- Keywords:
Semaglutide;
Chemical and drug-induced liver injury;
Severe liver injury
- From:
Adverse Drug Reactions Journal
2023;25(12):763-765
- CountryChina
- Language:Chinese
-
Abstract:
A 25-year-old woman received subcutaneous injection of semaglutide injection (semaglutide) 0.5 mg by herself for weight loss. She developed nausea and vomiting after medication but did not pay much attention to. On the 2nd week, semaglutide 1 mg was injected subcutaneously. Symptoms such as nausea and vomiting were aggravated, followed by stomach pain and distension, which could not be relieved. Laboratory tests showed alanine aminotransferase (ALT) 1 687 U/L, aspartate aminotransferase (AST) 809 U/L, alkaline phosphatase (ALP) 167 U/L, total bile acid (TBA) 178.8 μmol/L, total bilirubin(TBil) 106.3 μmol/L, direct bilirubin 64.0 μmol/L, and indirect bilirubin (IBil) 42.3 μmol/L. After excluding causes like viral hepatitis, autoimmune liver disease, obstructive jaundice, and concomitant drugs, acute liver injury caused by semaglutide was considered, and liver-protective treatments were given. Due to poor therapeutic effects, artificial liver treatment was given once, and then liver protective treatments were continued. On day 17 of treatment, laboratory tests showed ALT 579 U/L, AST 583 U/L, ALP 180 U/L, TBA 231.8 μmol/L, TBil 344.8 μmol/L, DBil 233.8 μmol/L, and IBil 111.0 μmol/L. After 6 months of treatments, the patient′s liver function returned to normal, with laboratory tests results of ALT 56 U/L, AST 33 U/L, ALP 99 U/L, TBA 2.7 μmol/L, TBil 10.5 μmol/L, DBil 3.2 μmol/L, and IBil 7.3 μmol/L.
